Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 LIMITATIONS
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 NORTH AMERICA STROKE MARKET, REGULATORY FRAMEWORK
5.1 REGULATION IN U.S.
5.2 REGULATION IN EUROPE
5.3 REGULATION IN CHINA
5.4 REGULATION IN JAPAN
5.5 REGULATION IN SOUTH AFRICA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING INCIDENCES OF STROKE DRIVE DEMAND FOR TREATMENTS
6.1.2 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASES
6.1.3 INCREASING DIABETIC AND OBESE POPULATIONS ELEVATE STROKE RISKS
6.1.4 ADVANCEMENTS IN MEDICAL TECHNOLOGY IMPROVE STROKE CARE OUTCO.MES
6.2 RESTRAINTS
6.2.1 HIGH COST OF DIAGNOSIS
6.2.2 INCREASE IN PRODUCT RECALL
6.3 OPPORTUNITIES
6.3.1 DEVELOPMENT OF ADVANCED THERAPEUTICS FOR STROKES
6.3.2 EXPANSION IN STROKE REHABILITATION SERVICES
6.3.3 INNOVATIVE TREATMENTS IN PIPELINE FOR STROKE TREATMENT
6.4 CHALLENGES
6.4.1 FALSE DIAGNOSIS IN STROKES
6.4.2 COMPLICATIONS ASSOCIATED WITH MANAGING STROKE
7 NORTH AMERICA STROKE MARKET, BY TYPE
7.1 OVERVIEW
7.2 ISCHEMIC STROKE
7.2.1 THROMBOTIC (CEREBRAL THROMBOSIS)
7.2.2 EMBOLIC (CEREBRAL EMBOLISM)
7.3 HEMORRHAGIC STROKE
7.3.1 SUBARACHNOID HEMORRHAGE
7.3.2 INTRACEREBRAL HEMORRHAGE
7.4 TRANSIENT ISCHEMIC ATTACT (TIA)
8 NORTH AMERICA STROKE MARKET, BY GENDER
8.1 OVERVIEW
8.2 FEMALE
8.3 MALE
9 NORTH AMERICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT
9.1 OVERVIEW
9.2 TREATMENT
9.2.1 BY TREATMENT TYPE
9.2.1.1 MEDICATION
9.2.1.1.1 MEDICATION, BY CLASS
9.2.1.1.1.1 BLOOD PRESSURE MEDICINES
9.2.1.1.1.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
9.2.1.1.1.1.2 RAMIPRIL
9.2.1.1.1.1.3 LISINOPRIL
9.2.1.1.1.1.4 ENALAPRIL
9.2.1.1.1.1.5 PERINDOPRIL
9.2.1.1.1.1.6 OTHER
9.2.1.1.1.2 THIAZIDE DIURETICS
9.2.1.1.1.2.1 INDAPAMIDE
9.2.1.1.1.2.2 BENDROFLUMETHIAZIDE
9.2.1.1.1.2.3 SPIRONOLACTONE
9.2.1.1.1.2.4 AMILORIDE
9.2.1.1.1.2.5 OTHER
9.2.1.1.1.3 CALCIUM CHANNEL BLOCKERS
9.2.1.1.1.3.1 AMLODIPINE
9.2.1.1.1.3.2 NIFEDIPINE
9.2.1.1.1.3.3 VERAPAMIL
9.2.1.1.1.3.4 NICARDIPINE
9.2.1.1.1.3.5 FELODIPINE
9.2.1.1.1.3.6 NIMODIPINE
9.2.1.1.1.3.7 OTHERS
9.2.1.1.1.4 BETA BLOCKERS
9.2.1.1.1.4.1 ATENOLOL
9.2.1.1.1.4.2 BISOPROLOL
9.2.1.1.1.4.3 LABETOLOL
9.2.1.1.1.4.4 OTHERS
9.2.1.1.1.5 ALPHA-BLOCKERS
9.2.1.1.1.5.1 DOXAZOSIN
9.2.1.1.1.5.2 OTHERS
9.2.1.1.1.6 OTHERS
9.2.1.1.1.7 ANTIPLATELET DRUGS
9.2.1.1.1.7.1 ASPIRIN
9.2.1.1.1.7.2 CLOPIDOGREL
9.2.1.1.1.7.3 DIPYRIDAMOLE
9.2.1.1.1.7.4 TICLOPIDINE
9.2.1.1.1.7.5 OTHERS
9.2.1.1.1.8 ANTICOAGULANTS
9.2.1.1.1.8.1 WARFARIN
9.2.1.1.1.8.2 APIXABAN
9.2.1.1.1.8.3 DABIGATRAN
9.2.1.1.1.8.4 HEPARIN
9.2.1.1.1.8.5 RIVAROXABAN
9.2.1.1.1.8.6 OTHERS
9.2.1.1.1.9 TISSUE PLASMINOGEN ACTIVATOR (TPA)
9.2.1.1.1.9.1 ALTEPLASE
9.2.1.1.1.9.2 TENECTEPLASE
9.2.1.1.1.9.3 RETEPLASE
9.2.1.1.1.9.4 ANISTREPLASE
9.2.1.1.1.9.5 OTHERS
9.2.1.1.1.10 STATINS
9.2.1.1.1.10.1.1 ATORVASTATIN
9.2.1.1.1.10.1.2 SIMVASTATIN
9.2.1.1.1.10.1.3 LOVASTATIN
9.2.1.1.1.10.1.4 ROSUVASTATIN
9.2.1.1.1.10.1.5 FLUVASTATIN
9.2.1.1.1.10.1.6 PRAVASTATIN
9.2.1.1.1.10.1.7 PITAVASTATIN
9.2.1.1.1.10.1.8 OTHERS
9.2.1.1.1.11 VITAMIN K
9.2.1.1.1.12 SUPPORTIVE MEDICATION
9.2.1.1.1.12.1 NUTRITIONAL SUPPLEMENTS
9.2.1.1.1.12.2 ANTIPYRETICS
9.2.1.1.1.12.3 OTHERS
9.2.1.1.2 MEDICATION, BY DRUG TYPE
9.2.1.1.2.1 BRANDED
9.2.1.1.2.1.1 ACTIVASE
9.2.1.1.2.1.2 EDOBAXAN
9.2.1.1.2.1.3 COUMADIN
9.2.1.1.2.1.4 HEPARIN LEO
9.2.1.1.2.1.5 DUOPLAVIN
9.2.1.1.2.1.6 AGGRENOX
9.2.1.1.2.1.7 RETAVASE
9.2.1.1.2.1.8 JANTOVEN
9.2.1.1.2.1.9 CATHFLO
9.2.1.1.2.1.10 OTHER
9.2.1.1.2.2 GENERIC
9.2.1.1.3 MEDICATION, BY ROUTE OF ADMINISTRATION
9.2.1.1.3.1 ORAL
9.2.1.1.3.1.1 TABLET
9.2.1.1.3.1.2 CAPSULES
9.2.1.1.3.1.3 OTHERS
9.2.1.1.3.2 PARENTERAL
9.2.1.1.3.2.1 INTRAVENOUS
9.2.1.1.3.2.2 SUBCUTANEOUS
9.2.1.1.3.3 OTHERS
9.2.1.1.4 MEDICATION, BY MODE OF PURCHASE
9.2.1.1.4.1 PRESCRIPTION
9.2.1.1.4.2 OVER THE COUNTER (OTC)
9.2.1.1.5 MEDICATION, BY THERAPY TYPE
9.2.1.1.5.1 COMBINATION THERAPY
9.2.1.1.5.2 MONOTHERAPY
9.2.1.2 SURGERY
9.2.1.2.1 EMBOLIC COILS
9.2.1.2.2 ASPIRATION CATHETERS
9.2.1.2.3 STENT RETRIEVER
9.2.1.2.4 SURGICAL CLIPPING
9.2.1.2.5 OTHERS
9.2.1.3 OTHERS THERAPY
9.2.1.3.1 PHYSICAL THERAPY
9.2.1.3.2 OCCUPATIONAL THERAPY
9.2.1.3.3 SPEECH THERAPY
9.2.1.3.4 OTHERS
9.3 DIAGNOSIS
9.3.1 IMAGING TEST
9.3.1.1 COMPUTERIZED TOMOGRAPHY (CT) SCAN
9.3.1.2 MAGNETIC RESONANCE IMAGING (MRI)
9.3.1.3 CAROTID ULTRASOUND
9.3.1.4 CEREBRAL ANGIOGRAM
9.3.2 BLOOD TEST
9.3.3 ECHOCARDIOGRAM
9.3.4 LUMBAR PUNCTURE
9.3.5 OTHERS
10 NORTH AMERICA STROKE MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 DIRECT
10.3 RETAIL
10.4 ONLINE
11 NORTH AMERICA STROKE MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS & CLINICS
11.3 SPECIALTY CLINICS
11.4 AMBULATORY SURGICAL CENTER
11.5 HOMECARE
11.6 LABORATORIES
11.7 OTHERS
12 NORTH AMERICA STROKE MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA STROKE MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 BRISTOL-MYERS SQUIBB COMPANY
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.2 F. HOFFMANN-LA ROCHE LTD
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 DAIICHI SANKYO COMPANY, LIMITED
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 SANOFI
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 AMNEAL PHARMACEUTICALS LLC
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ASTRAZENECA
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 BAYER AG
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 FRESENIUS SE & CO. KGAA
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 GLENMARK PHARMACEUTICALS LTD.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 JOHNSON & JOHNSON SERVICES, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 LUPIN
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.14 MEDTRONIC
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENT
15.15 PENUMBRA, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 PFIZER INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 SANDOZ AG
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 TEVA PHARMACEUTICALS USA, INC.
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENT
15.19 VIATRIS INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 2 NORTH AMERICA ISCHEMIC STROKE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 NORTH AMERICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 4 NORTH AMERICA HEMORRHAGIC STROKE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 NORTH AMERICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 NORTH AMERICA TRANSIENT ISCHEMIC ATTACT (TIA) IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 7 NORTH AMERICA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 8 NORTH AMERICA FEMALE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 NORTH AMERICA MALE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 NORTH AMERICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 11 NORTH AMERICA TREATMENT IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 NORTH AMERICA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 NORTH AMERICA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 14 NORTH AMERICA BLOOD PRESSURE MEDICINES IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 15 NORTH AMERICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 16 NORTH AMERICA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 17 NORTH AMERICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 18 NORTH AMERICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 19 NORTH AMERICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 20 NORTH AMERICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 21 NORTH AMERICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 22 NORTH AMERICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 23 NORTH AMERICA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 24 NORTH AMERICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 25 NORTH AMERICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 26 NORTH AMERICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 27 NORTH AMERICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 28 NORTH AMERICA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 NORTH AMERICA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 NORTH AMERICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 31 NORTH AMERICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 32 NORTH AMERICA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 33 NORTH AMERICA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 NORTH AMERICA DIAGNOSIS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 NORTH AMERICA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 36 NORTH AMERICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 NORTH AMERICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 38 NORTH AMERICA DIRECT IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 NORTH AMERICA RETAIL IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 NORTH AMERICA ONLINE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 NORTH AMERICA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 42 NORTH AMERICA HOSPITALS & CLINICS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 43 NORTH AMERICA SPECIALTY CLINICS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 NORTH AMERICA AMBULATORY SURGICAL CENTER IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 NORTH AMERICA HOMECARE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 46 NORTH AMERICA LABORATORIES IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 NORTH AMERICA OTHERS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 48 NORTH AMERICA STROKE MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 49 NORTH-AMERICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 NORTH-AMERICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 NORTH-AMERICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 NORTH-AMERICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 53 NORTH-AMERICA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 NORTH-AMERICA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 55 NORTH-AMERICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 56 NORTH-AMERICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 57 NORTH-AMERICA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 58 NORTH-AMERICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 59 NORTH-AMERICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 60 NORTH-AMERICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 61 NORTH-AMERICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 62 NORTH-AMERICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 63 NORTH-AMERICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 64 NORTH-AMERICA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 65 NORTH-AMERICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 66 NORTH-AMERICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 NORTH-AMERICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 NORTH-AMERICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 69 NORTH-AMERICA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 NORTH-AMERICA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 NORTH-AMERICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 72 NORTH-AMERICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 NORTH-AMERICA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 NORTH-AMERICA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 NORTH-AMERICA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 NORTH-AMERICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 NORTH-AMERICA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 78 NORTH-AMERICA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 79 NORTH-AMERICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 80 U.S. STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 U.S. ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 U.S. HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 U.S. STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 84 U.S. TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 U.S. MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 86 U.S. BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 87 U.S. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 88 U.S. THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 89 U.S. CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 90 U.S. BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 91 U.S. ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 92 U.S. ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 93 U.S. ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 94 U.S. TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 95 U.S. STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 96 U.S. SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 97 U.S. MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 98 U.S. BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 U.S. MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 100 U.S. ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 U.S. PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 U.S. MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 103 U.S. MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 U.S. SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 U.S. OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 U.S. DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 U.S. IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 U.S. STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 109 U.S. STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 110 U.S. STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 111 CANADA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 CANADA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 CANADA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 CANADA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 115 CANADA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 CANADA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 117 CANADA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 118 CANADA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 119 CANADA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 120 CANADA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 121 CANADA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 122 CANADA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 123 CANADA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 124 CANADA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 125 CANADA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 126 CANADA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 127 CANADA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 128 CANADA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 CANADA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 CANADA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 131 CANADA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 CANADA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 CANADA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 134 CANADA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 CANADA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 CANADA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 CANADA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 CANADA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 CANADA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 140 CANADA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 141 CANADA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 142 MEXICO STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 MEXICO ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 MEXICO HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 MEXICO STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 146 MEXICO TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 MEXICO MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 148 MEXICO BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 149 MEXICO ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 150 MEXICO THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 151 MEXICO CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 152 MEXICO BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 153 MEXICO ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 154 MEXICO ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 155 MEXICO ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 156 MEXICO TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 157 MEXICO STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 158 MEXICO SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 159 MEXICO MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 160 MEXICO BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 MEXICO MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 162 MEXICO ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 MEXICO PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 MEXICO MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 165 MEXICO MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 MEXICO SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 MEXICO OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 MEXICO DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 MEXICO IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 MEXICO STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 171 MEXICO STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 172 MEXICO STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA STROKE MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA STROKE MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA STROKE MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA STROKE MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA STROKE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA STROKE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA STROKE MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA STROKE MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA STROKE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA STROKE MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCES OF STROKE DRIVE DEMAND FOR TREATMENTS IS EXPECTED TO DRIVE THE NORTH AMERICA STROKE MARKET GROWTH IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 12 ISCHEMIC STROKE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA STROKE MARKET IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 13 NORTH AMERICA STROKE MARKET EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA STROKE MARKET
FIGURE 16 NORTH AMERICA STROKE MARKET: BY TYPE, 2024
FIGURE 17 NORTH AMERICA STROKE MARKET: BY TYPE, 2025-2032 (USD THOUSAND)
FIGURE 18 NORTH AMERICA STROKE MARKET: BY TYPE, CAGR (2025-2032)
FIGURE 19 NORTH AMERICA STROKE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA STROKE MARKET: BY GENDER, 2024
FIGURE 21 NORTH AMERICA STROKE MARKET: BY GENDER, 2025 TO 2032 (USD THOUSAND)
FIGURE 22 NORTH AMERICA STROKE MARKET: BY GENDER, CAGR (2025- 2032)
FIGURE 23 NORTH AMERICA STROKE MARKET: BY GENDER, LIFELINE CURVE
FIGURE 24 NORTH AMERICA STROKE MARKET: BY DIAGNOSIS AND TREATMENT, 2024
FIGURE 25 NORTH AMERICA STROKE MARKET: BY DIAGNOSIS AND TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 26 NORTH AMERICA STROKE MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2025-2032)
FIGURE 27 NORTH AMERICA STROKE MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE
FIGURE 28 NORTH AMERICA STROKE MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 29 NORTH AMERICA STROKE MARKET: BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
FIGURE 30 NORTH AMERICA STROKE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 31 NORTH AMERICA STROKE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 32 NORTH AMERICA STROKE MARKET: BY END USER, 2024
FIGURE 33 NORTH AMERICA STROKE MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 34 NORTH AMERICA STROKE MARKET: BY END USER, CAGR (2025-2032)
FIGURE 35 NORTH AMERICA STROKE MARKET: BY END USER, LIFELINE CURVE
FIGURE 36 NORTH AMERICA STROKE MARKET: SNAPSHOT (2024)
FIGURE 37 NORTH AMERICA STROKE MARKET: COMPANY SHARE 2024 (%)
